keyword
MENU ▼
Read by QxMD icon Read
search

Modern therapy of acute lymphoblastic leukemia

keyword
https://www.readbyqxmd.com/read/27913532/t-cell-acute-lymphoblastic-leukemia
#1
Elizabeth A Raetz, David T Teachey
T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. Although very similar regimens are used to treat T-ALL and B-ALL, distinctions in response to different elements of therapy have been observed. Similar to B-ALL, the key prognostic determinant in T-ALL is minimal residual disease (MRD) response. Unlike B-ALL, other factors including age, white blood cell count at diagnosis, and genetics of the ALL blasts are not independently prognostic when MRD response is included...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913529/ph-like-acute-lymphoblastic-leukemia
#2
Thai Hoa Tran, Mignon L Loh
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a newly identified high-risk (HR) B-lineage ALL subtype, accounting for ∼15% of children with National Cancer Institute-defined HR B-ALL. It occurs more frequently in adolescents and adults, having been reported in as much as 27% of young adults with ALL between 21 and 39 years of age. It exhibits adverse clinical features, confers a poor prognosis, and harbors a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27800262/ophthalmologic-findings-in-children-with-leukemia-a-single-center-study
#3
Betül Orhan, Barış Malbora, Sezin Akça Bayar, Zekai Avcı, Bülent Alioğlu, Namık Özbek
OBJECTIVES: Ophthalmologic disease in patients with acute leukemia occurs due to primary leukemic infiltration (involvement), or secondary to the disease and its treatment. In recent years the life expectancy of acute leukemia patients has increased with the advent of modern therapies. The present study aimed to determine the incidence of ocular manifestations in children with acute leukemia. MATERIALS AND METHODS: The study included 120 patients diagnosed with acute leukemia at Başkent University Hospital, Pediatric Hematology Department between 1995 and 2010...
April 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27536191/concurrent-hypopituitarism-and-leukemic-retinopathy-in-a-child-with-b-precursor-acute-lymphoblastic-leukemia-and-isolated-central-nervous-system-relapse
#4
K H Wu, H P Wu, H J Lin, C H Wang, H Y Chen, T Weng, C T Peng, Y H Chao
Hypopituitarism in leukemia is very rare. In addition, central nervous system (cns) relapse and leukemic retinopathy in childhood acute lymphoblastic leukemia (all) have declined with the use of modern systemic chemotherapy that includes cns prophylaxis. Here, we report the case of a 4-year-old girl who received chemotherapy and intrathecal therapy without cns radiation after a diagnosis of B-precursor all without cns involvement. Three months after chemotherapy completion, she presented with lower-extremity weakness and was diagnosed with an isolated cns relapse...
August 2016: Current Oncology
https://www.readbyqxmd.com/read/27460684/nanomedicine-approaches-in-acute-lymphoblastic-leukemia
#5
REVIEW
Andra-Sorina Tatar, Timea Nagy-Simon, Ciprian Tomuleasa, Sanda Boca, Simion Astilean
Acute lymphoblastic leukemia (ALL) is the malignancy with the highest incidence amongst children (26% of all cancer cases), being surpassed only by the cancers of the brain and of the nervous system. The most recent research on ALL is focusing on new molecular therapies, like targeting specific biological structures in key points in the cell cycle, or using selective inhibitors for transmembranary proteins involved in cell signalling, and even aiming cell surface receptors with specifically designed antibodies for active targeting...
September 28, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27382259/drugs-under-preclinical-and-clinical-study-for-treatment-of-acute-and-chronic-lymphoblastic-leukemia
#6
REVIEW
Joe Antony Jacob, Jumah Masoud Mohammad Salmani, Baoan Chen
Targeted therapy has modernized the treatment of both chronic and acute lymphoblastic leukemia. The introduction of monoclonal antibodies and combinational drugs has increased the survival rate of patients. Preclinical studies with various agents have resulted in positive outputs with Phase III trial drugs and monoclonal antibodies entering clinical trials. Most of the monoclonal antibodies target the CD20 and CD22 receptors. This has led to the approval of a few of these drugs by the US Food and Drug Administration...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27246140/volume-outcome-relationships-in-pediatric-acute-lymphoblastic-leukemia-association-between-hospital-pediatric-and-pediatric-oncology-volume-with-mortality-and-intensive-care-resources-during-initial-therapy
#7
Jennifer J Wilkes, Sean Hennessy, Rui Xiao, Susan Rheingold, Alix E Seif, Yuan-Shung Huang, Neika Vendetti, Yimei Li, Rochelle Bagatell, Richard Aplenc, Brian T Fisher
BACKGROUND: There are few contemporary studies of volume-outcome relationships in pediatric oncology. Children with acute lymphoblastic leukemia (ALL) are treated at a wide variety of hospitals. We investigated if inpatient hospital volume influences outcomes. The objective of this study was to evaluate the relationship between inpatient pediatric and pediatric oncology volume and mortality and intensive care resources (ICU care). We hypothesized an inverse relationship between volume and these outcomes...
July 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27177145/effects-of-race-ethnicity-and-socioeconomic-status-on-outcome-in-childhood-acute-lymphoblastic-leukemia
#8
Sahaja Acharya, Samantha Hsieh, Eric T Shinohara, Todd DeWees, Haydar Frangoul, Stephanie M Perkins
With modern therapy, overall survival (OS) for children with acute lymphoblastic leukemia approaches 90%. However, inferior outcomes for minority children have been reported. Data on the effects of ethnicity/race as it relates to socioeconomic status are limited. Using state cancer registry data from Texas and Florida, we evaluated the impact of neighborhood-level poverty rate and race/ethnicity on OS for 4719 children with acute lymphoblastic leukemia. On multivariable analysis, patients residing in neighborhoods with the highest poverty rate had a 1...
July 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27161748/po-59-hemorheologic-disturbances-as-thrombosis-risk-factor-in-patients-with-some-myeloproliferative-neoplasms
#9
E V Roitman, I M Kolesnikova, I L Davydkin, N S Kozlova, S A Roumiantsev
INTRODUCTION: In today's antithrombotic prevention we forget that hemorheologic abnormalities are part of Virchow's triad. Isn't this one of reasons that venous thromboembolism (VTE) including catheter-related thrombosis (CRT) retain high frequency despite of modern antithrombotic therapy? AIM: The aim was to investigate rheological behavior of blood in patients with some myeloproliferative neoplasms. MATERIALS AND METHODS: The study included 16 adults with Polycythemia Vera (PV), 42 young with acute lymphoblastic leukemia (ALL), and 67 healthy donors as control group...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27094615/the-prognosis-of-adult-burkitt-s-cell-leukemia-in-real-life-clinical-practice
#10
Ümit Yavuz Malkan, Gürsel Güneş, Hakan Göker, İbrahim C Haznedaroğlu, Kadir Acar, Eylem Eliaçık, Sezgin Etgül, Tuncay Aslan, Seda Balaban, Haluk Demiroğlu, Osman I Özcebe, Nilgün Sayınalp, Salih Aksu, Yahya Büyükaşık
INTRODUCTION: Many studies reported an improved prognosis in the patients with Burkitt's lymphoma obviating the need of stem cell transplantation. However, prognosis of the advanced disease (i.e. Burkitt's cell leukemia) has not been reported with current treatment modalities except for a few prospective trials. The aim of this study is to compare the prognoses of the Burkitt's cell leukemia (BL) patients with similarly treated and not transplanted other types of acute lymphoblastic leukemia (ALL) patients and with ALL cases that underwent allogeneic stem cell transplantation (ASCT) in their first remissions...
April 18, 2016: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/26928953/dna-methylation-adds-prognostic-value-to-minimal-residual-disease-status-in-pediatric-t-cell-acute-lymphoblastic-leukemia
#11
Magnus Borssén, Zahra Haider, Mattias Landfors, Ulrika Norén-Nyström, Kjeld Schmiegelow, Ann E Åsberg, Jukka Kanerva, Hans O Madsen, Hanne Marquart, Mats Heyman, Magnus Hultdin, Göran Roos, Erik Forestier, Sofie Degerman
BACKGROUND: Despite increased knowledge about genetic aberrations in pediatric T-cell acute lymphoblastic leukemia (T-ALL), no clinically feasible treatment-stratifying marker exists at diagnosis. Instead patients are enrolled in intensive induction therapies with substantial side effects. In modern protocols, therapy response is monitored by minimal residual disease (MRD) analysis and used for postinduction risk group stratification. DNA methylation profiling is a candidate for subtype discrimination at diagnosis and we investigated its role as a prognostic marker in pediatric T-ALL...
July 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/26679753/lymphoblastic-lymphoma-an-updated-review-on-biology-diagnosis-and-treatment
#12
REVIEW
Renato Bassan, Elena Maino, Sergio Cortelazzo
Lymphoblastic lymphoma is a rare aggressive neoplasm of T-/B-precursors resembling acute lymphoblastic leukemia, with no or limited bone marrow involvement (<25%), that develops more frequently in children and young adults and is typically characterized by a grossly enlarged mediastinum, and whose diagnostic hallmark is the expression of a T-/B-precursor cell immunophenotype, the T-cell subset accounting for 90% of all cases. The adoption of pediatric-derived, intensive lymphoblastic leukemia-like protocols led to significantly improved results, with survival rates of about 70% and 90% in adults and children, respectively...
May 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/26335422/paving-the-road-ahead-for-cd19-car-t-cell-therapy
#13
REVIEW
Anandani Nellan, Daniel W Lee
PURPOSE OF REVIEW: Modern immunotherapies, most notably in the form of anti-CD19 chimeric antigen receptor (CAR) T cells, have produced significant clinical responses in otherwise refractory pre-B-cell acute lymphoblastic leukemia patients. Several groups have simultaneously reported robust response rates in children and adults alike. These early studies indicate an impending shift in paradigm for the treatment of acute lymphoblastic leukemia. Incorporating CD19 CAR T-cell therapy into upfront or salvage regimens has its challenges and opportunities...
November 2015: Current Opinion in Hematology
https://www.readbyqxmd.com/read/26314268/-acute-leukemia-in-adults
#14
REVIEW
E Eigendorff, A Hochhaus
BACKGROUND: The prognosis of adult patients with acute leukemia has continuously improved over the years due to the introduction of new diagnostic and therapeutic procedures and progress in the field of supportive therapy. METHODS: This article gives an overview of the currently available options and the clinical approach to the diagnostics and therapy of acute leukemia. RESULTS: The standardization as well as improvements in diagnostic procedures, in particular by immunocytological and genetic procedures, allow a more rapid determination of the exact diagnosis...
September 2015: Der Pathologe
https://www.readbyqxmd.com/read/26101530/increased-body-mass-index-during-therapy-for-childhood-acute-lymphoblastic-leukemia-a-significant-and-underestimated-complication
#15
Helen C Atkinson, Julie A Marsh, Shoshana R Rath, Rishi S Kotecha, Hazel Gough, Mandy Taylor, Thomas Walwyn, Nicholas G Gottardo, Catherine H Cole, Catherine S Choong
Objective & Design. We undertook a retrospective review of children diagnosed with acute lymphoblastic leukemia (ALL) and treated with modern COG protocols (n = 80) to determine longitudinal changes in body mass index (BMI) and the prevalence of obesity compared with a healthy reference population. Results. At diagnosis, the majority of patients (77.5%) were in the healthy weight category. During treatment, increases in BMI z-scores were greater for females than males; the prevalence of obesity increased from 10...
2015: International Journal of Pediatrics
https://www.readbyqxmd.com/read/25999456/monoclonal-antibodies-in-acute-lymphoblastic-leukemia
#16
REVIEW
Elias Jabbour, Susan O'Brien, Farhad Ravandi, Hagop Kantarjian
With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity...
June 25, 2015: Blood
https://www.readbyqxmd.com/read/25929769/minimal-residual-disease-monitoring-in-adult-all-to-determine-therapy
#17
REVIEW
Renato Bassan, Orietta Spinelli
Almost 90 % of children and 50 % of adults with acute lymphoblastic leukemia (ALL) are cured by modern treatment regimens, with significant variations due to several disease- and host-related characteristics. The attainment of an early remission and the avoidance of relapse and treatment-related mortality are the fundamental therapeutic steps. In remission patients, the assessment of the disease response to early intensive therapy through the detection and monitoring of minimal residual disease (MRD) can accurately refine the individual prognosis and is increasingly used to support a risk-oriented treatment strategy...
June 2015: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/25614322/pharmacogenetics-predictive-of-response-and-toxicity-in-acute-lymphoblastic-leukemia-therapy
#18
REVIEW
Lin Mei, Evelena P Ontiveros, Elizabeth A Griffiths, James E Thompson, Eunice S Wang, Meir Wetzler
Acute lymphoblastic leukemia (ALL) is a relatively rare disease in adults accounting for no more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in whom significant improvements in long term survival and even cure have been achieved over the last 30years, adult ALL remains a significant challenge. Overall survival in this group remains a relatively poor 20-40%. Modern research has focused on improved pharmacokinetics, novel pharmacogenetics and personalized principles to optimize the efficacy of the treatment while reducing toxicity...
July 2015: Blood Reviews
https://www.readbyqxmd.com/read/24904821/role-of-integrin-alpha4-in-drug-resistance-of-leukemia
#19
REVIEW
Stephanie Shishido, Halvard Bönig, Yong-Mi Kim
Chemotherapeutic drug resistance in acute lymphoblastic leukemia (ALL) is a significant problem, resulting in poor responsiveness to first-line treatment or relapse after transient remission. Classical anti-leukemic drugs are non-specific cell cycle poisons; some more modern drugs target oncogenic pathways in leukemia cells, although in ALL these do not play a very significant role. By contrast, the molecular interactions between microenvironment and leukemia cells are often neglected in the design of novel therapies against drug resistant leukemia...
2014: Frontiers in Oncology
https://www.readbyqxmd.com/read/23838315/generation-of-tumor-antigen-specific-t-cell-lines-from-pediatric-patients-with-acute-lymphoblastic-leukemia-implications-for-immunotherapy
#20
Gerrit Weber, Ignazio Caruana, Rayne H Rouce, A John Barrett, Ulrike Gerdemann, Ann M Leen, Karen R Rabin, Catherine M Bollard
PURPOSE: Although modern cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 80%, the outlook remains poor in patients with high-risk disease and those who relapse, especially when allogeneic hematopoietic stem cell transplantation is not feasible. Strategies to improve outcome and prevent relapse are therefore required. Immunotherapy with antigen-specific T cells can have antileukemic activity without the toxicities seen with intensive chemotherapy, and therefore represents an attractive strategy to improve the outcome of high-risk patients with ALL...
September 15, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
41491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"